Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Chan, S. L.; Kudo, M.; Lau, G.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; Rimassa, L.; Breder, V. V.; Vasilyev, A.; Heurgue, A.; Tam, V.; Mody, K.; Thungappa, S. C.; He, P.; Negro, A.; Sangro, B. |
| Abstract Title: | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900367 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.379 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 379 -- Meeting was conducted online as well as in person -- Source: Wos |
